このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Minimally Invasive Surgery for Spontaneous Deep Intracerebral Hemorrhage (MIS-DEEP ICH)

2026年9月28日 更新者:Tam Anh Research Institute

Effectiveness and Safety of Minimally Invasive Surgery for Spontaneous Deep Intracerebral Hemorrhage: A Prospective and Retrospective Observational Cohort Study

This observational cohort study evaluates the real-world effectiveness and safety of minimally invasive surgery (MIS) versus standard medical management in adults with spontaneous deep intracerebral hemorrhage. Patients presenting to Tam Anh General Hospital and People's Hospital 115 within 72 hours of hemorrhage onset will be enrolled and followed for 180 days. Clinical, radiological, and treatment-related variables will be collected, with primary outcome measures including survival and functional outcomes during follow-up period.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Spontaneous deep intracerebral hemorrhage (ICH) is a severe neurological condition associated with high mortality and significant long-term disability. Outcomes remain unsatisfactory with standard medical management alone, and conventional craniotomy has not consistently demonstrated a functional benefit. Minimally invasive surgery (MIS), including neuronavigation-guided parafascicular techniques, has been introduced to achieve hematoma evacuation while minimizing damage to surrounding brain structures and subcortical white-matter tracts. While increasing evidence supports the use of MIS in lobar ICH, evidence in patients with basal ganglia hemorrhage remains limited. In addition, previous studies have largely focused on surgery performed within the first 24 hours of symptom onset, and the effectiveness of MIS performed in the extended 24-to-72-hour window remains uncertain.

This retrospective and prospective, multicenter, observational cohort study is being conducted at Tam Anh General Hospital and People's Hospital 115. The study consists of both retrospective and prospective cohorts. The retrospective cohort includes patients treated from November 2024 onward, following approval by the Ministry of Health for the robotic-assisted intracerebral hematoma evacuation procedure at Tam Anh General Hospital, Ho Chi Minh City, and continues through the present. The prospective cohort is planned to enroll patients from June 2026 to June 2028. Eligible participants include those presenting with spontaneous basal ganglia ICH within 72 hours of symptom onset.

Management decisions, including the indication for MIS and the timing of surgical intervention, are determined solely by the treating physicians according to routine clinical practice. No treatment allocation or intervention is dictated by this protocol; instead, the study evaluates real-world clinical practices and outcomes.

Data will be recorded using standardized case report forms and electronic case report forms (CRFs/eCRFs). Collected information includes patient demographics, comorbidities, neurological presentation, laboratory results, radiological characteristics, intraoperative details for patients undergoing MIS, intensive care management, hospital course, and follow-up evaluations. All participants will be followed for 180 days after treatment.

The primary outcome measure is functional status at 180 days. Safety outcomes include mortality and treatment-related adverse events. Prespecified multivariable analyses will be conducted to address potential confounding by indication. Subgroup analyses are planned to compare outcomes according to the timing of MIS (0-24 hours versus 24-72 hours) and other clinically relevant factors.

By evaluating patients with basal ganglia hemorrhage treated across specialized Vietnamese stroke centers, this study seeks to provide real-world evidence regarding the effectiveness and safety of MIS for deep ICH and to support future research on patient selection and optimal timing of intervention.

研究の種類

観察的

入学 (推定)

300

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Huy Tan Chu, MD-PhD
  • 電話番号:1668 +842839976276
  • メール:huyct@tamri.vn

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

The study population consists of adult patients with spontaneous basal ganglia intracerebral hemorrhage treated at participating stroke centers in Vietnam. Eligible patients are aged 18 to 80 years and have a diagnosis of spontaneous basal ganglia hemorrhage confirmed by non-contrast computed tomography (CT). Patients must have a hematoma volume between 30 and 80 mL, calculated using the ABC/2 method, and be enrolled within 72 hours of symptom onset (or last known well time if symptom onset is unknown). Additional eligibility criteria include a Glasgow Coma Scale (GCS) score between 5 and 14 and a pre-stroke modified Rankin Scale (mRS) score of 0 to 1. The study aims to evaluate the effectiveness and safety of minimally invasive surgery compared with standard medical treatment in a real-world clinical setting and to provide evidence regarding patient selection and optimal timing of intervention for deep intracerebral hemorrhage.

説明

Inclusion Criteria:

  • Age 18 to 80 years
  • Spontaneous basal ganglia intracerebral hemorrhage confirmed by non-contrast CT
  • Hematoma volume between 30 and 80 mL (calculated using the ABC/2 method)
  • Time from symptom onset to enrollment ≤ 72 hours (for patients with an unknown onset time, the last known well time will be used)
  • Glasgow Coma Scale (GCS) score between 5 and 14
  • Pre-stroke modified Rankin Scale (mRS) score of 0 to 1

Exclusion Criteria:

  • Secondary intracerebral hemorrhage due to trauma, brain tumor, arteriovenous malformation, cerebral aneurysm, or hemorrhagic transformation of ischemic stroke
  • Infratentorial hemorrhage involving the brainstem or cerebellum
  • Primary thalamic hemorrhage
  • Intraventricular extension occupying more than 50% of either lateral ventricle
  • NIHSS score < 5
  • Bilaterally fixed and dilated pupils with no light reflexes
  • Decerebrate posturing
  • Platelet count < 75,000/μL
  • IINR > 1.4 after correction
  • Ongoing anticoagulation that cannot be rapidly reversed
  • Indication for long-term anticoagulation within 5 days of symptom onset
  • End-stage renal disease
  • End-stage liver disease
  • Presence of a mechanical heart valve
  • Comorbid condition associated with a life expectancy < 6 months
  • Inability or unwillingness of the participant or legally authorized representative to provide written informed consent

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:OTHER

コホートと介入

グループ/コホート
介入・治療
MIS Group

Participants with spontaneous deep intracerebral hemorrhage who receive standard medical treatment according to current clinical practice guidelines. Clinical and safety outcomes will be assessed through 180 days of follow-up.

Patients with spontaneous deep intracerebral hemorrhage who undergo minimally invasive surgery as part of routine clinical care. Decisions regarding surgical treatment and timing are made by the treating physicians according to standard practice. Clinical outcomes and safety outcomes will be evaluated through 180 days of follow-up.

Standard Medical Treatment Group

Participants with spontaneous deep intracerebral hemorrhage who receive standard medical treatment according to current clinical practice guidelines. Clinical and safety outcomes will be assessed through 180 days of follow-up.

Participants receive standard medical management according to current clinical practice guidelines for spontaneous intracerebral hemorrhage. Treatment decisions are made by the treating physicians. Clinical and safety outcomes will be evaluated through 180 days of follow-up.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Functional Outcome by modified Rankin Scale (mRS)
時間枠:180 days after symptom onset

Proportion of participants with a favorable functional outcome, defined as mRS score of 0 to 3.

Unit of Measure: Percentage of participants.

180 days after symptom onset
Functional Outcome by Utility-Weighted modified Rankin Scale (UW-mRS)
時間枠:180 days after symptom onset

Mean UW-mRS score at 180 days after symptom onset. The UW-mRS is a utility-based measure of functional outcome ranging from 0 (death) to 1 (no symptoms).

Unit of Measure: Score (range: 0 to 1)

180 days after symptom onset
Safety: All-Cause Mortality at 30 days
時間枠:30 days after symptom onset

All-cause mortality within 30 days after symptom onset. Unit of Measure: Percentage of participants

30 days after symptom onset
Safety: Change in Hematoma Volume (Δ volume)
時間枠:Within 24 hours after MIS (MIS group) or within 6-36 hours after the baseline CT scan (standard medical treatment group)

Δ volume calculated as the difference between hematoma volume measured on the follow-up CT scan (performed within 24 hours after minimally invasive surgery (MIS) for MIS group, or within 6-36 hours after baseline CT scan for standard medical treatment group) and that on the baseline CT scan (the first CT scan performed on hospital admission). Hematoma volume will be measured using the ABC/2 method.

Unit of Measure: Milliliters (mL)

Within 24 hours after MIS (MIS group) or within 6-36 hours after the baseline CT scan (standard medical treatment group)
Safety: Treatment-Related Complications
時間枠:From treatment initiation through 30 days after symptom onset

Occurrence of one or more treatment-related complications, including rebleeding, surgical site infection or meningitis, new-onset seizures, progressive cerebral edema, hydrocephalus requiring external ventricular drainage or shunt placement, hypotension or shock requiring specific treatment, and neurological readmission within 30 days.

Unit of Measure: Number of participants with one or more treatment-related complications

From treatment initiation through 30 days after symptom onset

二次結果の測定

結果測定
メジャーの説明
時間枠
Functional Outcome According to Timing of Minimally Invasive Surgery (MIS)
時間枠:180 days after symptom onset

Among participants treated with minimally invasive surgery (MIS), the proportion achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-3 at 180 days, and the median modified Rankin Scale (mRS) score at 180 days will be compared between participants undergoing MIS within 24 hours of symptom onset and those undergoing MIS within >24-72 hours after symptom onset.

Unit of Measure: Percentage of participants; Score (range: 0 to 6)

180 days after symptom onset
Safety: All-Cause Mortality According to Timing of Minimally Invasive Surgery (MIS)
時間枠:30 days after symptom onset

Among participants treated with MIS, all-cause mortality within 30 days after symptom onset will be compared between those undergoing MIS within 0-24 hours of symptom onset and those undergoing MIS within >24-72 hours after symptom onset.

Unit of Measure: Percentage of participants

30 days after symptom onset
Safety: Treatment-Related Complications According to Timing of Minimally Invasive Surgery (MIS)
時間枠:From treatment initiation through 30 days after symptom onset

Among participants treated with MIS, the occurrence of one or more treatment-related complications, including rebleeding, surgical site infection or meningitis, new-onset seizures, progressive cerebral edema, hydrocephalus requiring external ventricular drainage or shunt placement, hypotension or shock requiring specific treatment, and neurological readmission within 30 days, will be compared between those undergoing MIS within 24 hours of symptom onset and those undergoing MIS within >24-72 hours after symptom onset.

Unit of Measure: Number of participants with one or more treatment-related complications

From treatment initiation through 30 days after symptom onset

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年12月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年6月18日

QC基準を満たした最初の提出物

2026年7月15日

最初の投稿 (実際)

2026年7月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ICH-115TA

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。